Archives
(-)-Arctigenin: Precision MEK1 and iNOS Inhibitor for NF-...
(-)-Arctigenin: Precision MEK1 and iNOS Inhibitor for NF-κB Pathway Research
Executive Summary: (-)-Arctigenin is a bioactive small molecule natural product exhibiting potent inhibition of MEK1 (IC50 0.5 nM) and iNOS expression (IC50 10 nM), with applications in anti-inflammatory, antiviral, and neuroprotection research. It suppresses NF-κB signaling by blocking IκBα phosphorylation and p65 nuclear translocation, and inhibits HIV-1 replication in vitro. The compound is insoluble in water or ethanol but highly soluble in DMSO (≥17.2 mg/mL), and is supplied at >98% purity by APExBIO. Mechanistic studies reveal direct relevance to breast cancer cell invasion and tumor microenvironment modulation via targeted pathway inhibition (Li et al., 2022; APExBIO).
Biological Rationale
The NF-κB and MAPK/ERK signaling pathways are central to inflammatory and tumorigenic processes. Tumor-associated macrophages (TAMs) release extracellular vesicles (EVs) containing microRNAs (e.g., miR-660) that activate NF-κB p65, promoting cancer cell invasion and metastasis (Li et al., 2022). Agents that suppress iNOS and MEK1—key regulators in these pathways—offer translational value for cancer and immunology research. (-)-Arctigenin, a lignan isolated from Arctium lappa, has emerged as a dual-action inhibitor for these targets (APExBIO).
Mechanism of Action of (-)-Arctigenin
(-)-Arctigenin exerts its primary effects by inhibiting two major molecular targets:
- iNOS suppression: Inhibits LPS-induced iNOS expression by blocking IκBα phosphorylation and preventing p65 NF-κB nuclear translocation (IC50 10 nM) (APExBIO).
- MEK1 inhibition: Potently blocks mitogen-activated protein kinase kinase 1 (MEK1/MKK1) with IC50 of 0.5 nM, attenuating downstream MAPK/ERK signaling (Related Article).
- Kainate receptor binding: Directly binds kainate receptors, mediating neuroprotective effects in neuronal models (APExBIO).
- Antiviral activity: Inhibits in vitro HIV-1 replication at micromolar concentrations (APExBIO).
By targeting these pathways, (-)-Arctigenin disrupts key steps in cancer cell survival, migration, and immune evasion (see comparison: detailed mechanism mapping).
Evidence & Benchmarks
- Suppresses LPS-induced iNOS expression in macrophages (IC50 = 10 nM) via inhibition of IκBα phosphorylation and p65 nuclear import (APExBIO QC Data).
- Inhibits MEK1 (MKK1) kinase activity in vitro (IC50 = 0.5 nM), validated by HPLC and NMR purity metrics (>98%) (APExBIO).
- Reduces NF-κB p65 signaling, a key driver of tumor microenvironment remodeling in breast cancer models (Li et al., 2022).
- Inhibits HIV-1 replication in cellular assays at concentrations ≤10 μM (APExBIO).
- Demonstrates neuroprotective effects through kainate receptor binding (APExBIO).
Applications, Limits & Misconceptions
Core Applications:
- Dissection of NF-κB and MAPK/ERK signaling in cancer, inflammation, and neurobiology.
- Modeling tumor microenvironment modulation, particularly in studies focused on breast cancer and TAMs (Li et al., 2022).
- Antiviral mechanism research for HIV-1 and related viruses (APExBIO).
- Cell-based assay optimization for viability, proliferation, and cytotoxicity endpoints (Optimizing Cell Assays: This article extends cell assay optimization by detailing pathway-specific benchmarks for (-)-Arctigenin).
Common Pitfalls or Misconceptions
- Not a pan-inhibitor: (-)-Arctigenin does not broadly suppress all kinases or transcription factors; its action is selective for MEK1 and iNOS pathways (APExBIO).
- Solubility constraints: The compound is insoluble in water or ethanol—use DMSO (≥17.2 mg/mL) for stock solutions (APExBIO).
- Not suitable for long-term solution storage: Stock solutions are unstable over extended periods; prepare fresh aliquots for each experiment (APExBIO).
- No direct effect on non-NF-κB mediated pathways: Efficacy is reduced in cell types where iNOS/NF-κB signaling is not the primary driver (Precision Use-Cases: This guide clarifies limitations for off-pathway models).
- In vivo translation: Potency and bioavailability in vivo may differ from in vitro results; animal model-specific optimization is required (Applied Strategies: This resource updates practical considerations for translational use).
Workflow Integration & Parameters
For routine use, (-)-Arctigenin (SKU N2399) is supplied as a >98% pure solid by APExBIO. Dissolve in DMSO at concentrations up to 17.2 mg/mL. Store powder at -20°C desiccated; avoid repeated freeze-thaw cycles. Do not store stock solutions long-term. For iNOS inhibition, use at 10–100 nM; for MEK1 inhibition, 0.5–10 nM is effective in most cell lines. Verify pathway inhibition by immunoblot for IκBα, p65, and ERK1/2 phosphorylation. Quality control includes HPLC, NMR, and MSDS documentation ((-)-Arctigenin product page).
Conclusion & Outlook
(-)-Arctigenin is a potent, selective inhibitor of iNOS and MEK1, with well-defined anti-inflammatory and antiviral activities. Its role in modulating NF-κB and MAPK/ERK pathways positions it as a model compound for dissecting tumor microenvironment dynamics and neuroprotection. Continued development of pathway-selective inhibitors like (-)-Arctigenin will support advances in targeted cancer and inflammation research. For further application-specific protocols and troubleshooting, see Applied Research with (-)-Arctigenin, which delivers advanced guidance for bench scientists.